These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17913865)

  • 21. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.
    Mountzouros KT; Belanger KA; Howell AP; Bixler GS; Madore DV
    Infect Immun; 2002 Dec; 70(12):6576-82. PubMed ID: 12438327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Approach to the Discovery, Development, and Evaluation of a Novel Neisseria meningitidis Serogroup B Vaccine.
    Green LR; Eiden J; Hao L; Jones T; Perez J; McNeil LK; Jansen KU; Anderson AS
    Methods Mol Biol; 2016; 1403():445-69. PubMed ID: 27076147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.
    Williams JN; Skipp PJ; O'Connor CD; Christodoulides M; Heckels JE
    Infect Immun; 2009 Nov; 77(11):5080-9. PubMed ID: 19737898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins.
    Hung MC; Humbert MV; Laver JR; Phillips R; Heckels JE; Christodoulides M
    Vaccine; 2015 Aug; 33(36):4486-94. PubMed ID: 26207592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
    Lucidarme J; Louth J; Townsend-Payne K; Borrow R
    Methods Mol Biol; 2019; 1969():169-179. PubMed ID: 30877677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.
    Frasch CE; Borrow R; Donnelly J
    Vaccine; 2009 Jun; 27 Suppl 2():B112-6. PubMed ID: 19464093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum bactericidal antibody assays - The role of complement in infection and immunity.
    McIntosh ED; Bröker M; Wassil J; Welsch JA; Borrow R
    Vaccine; 2015 Aug; 33(36):4414-21. PubMed ID: 26187262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
    Balmer P; Beeslaar J; Findlow J; Srivastava A
    Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.
    Toropainen M; Saarinen L; Vidarsson G; Käyhty H
    Infect Immun; 2006 May; 74(5):2803-8. PubMed ID: 16622217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.
    Giuliani MM; Biolchi A; Serruto D; Ferlicca F; Vienken K; Oster P; Rappuoli R; Pizza M; Donnelly J
    Vaccine; 2010 Jul; 28(31):5023-30. PubMed ID: 20493284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
    Marshall HS; Richmond PC; Beeslaar J; Jiang Q; Jansen KU; Garcés-Sánchez M; Martinón-Torres F; Szenborn L; Wysocki J; Eiden J; Harris SL; Jones TR; Lee SS; Perez JL;
    Lancet Infect Dis; 2017 Jan; 17(1):58-67. PubMed ID: 27745812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
    McQuaid F; Snape MD; John TM; Kelly S; Robinson H; Houlden J; Voysey M; Toneatto D; Kitte C; Dull PM; Pollard AJ
    Pediatr Infect Dis J; 2014 Jul; 33(7):760-6. PubMed ID: 24722351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.
    Feiring B; Fuglesang J; Oster P; Naess LM; Helland OS; Tilman S; Rosenqvist E; Bergsaker MA; Nøkleby H; Aaberge IS
    Clin Vaccine Immunol; 2006 Jul; 13(7):790-6. PubMed ID: 16829617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroprevalence of bactericidal antibodies against serogroup B and C Meningococci in a University Hospital.
    Gioia CAC; Lemos APS; Gorla MCO; Mendoza-Sassi R; Figueredo BS; Ballester T; Von Groll A; Wedig B; Ethur NV; Bragança L; Silva PEA; Milagres LG
    Braz J Med Biol Res; 2017 Apr; 50(5):e5590. PubMed ID: 28443987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.
    Borrow R; Aaberge IS; Santos GF; Eudey TL; Oster P; Glennie A; Findlow J; Høiby EA; Rosenqvist E; Balmer P; Martin D
    Clin Diagn Lab Immunol; 2005 Aug; 12(8):970-6. PubMed ID: 16085915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.
    Welsch JA; Ram S; Koeberling O; Granoff DM
    J Infect Dis; 2008 Apr; 197(7):1053-61. PubMed ID: 18419542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.